Advertisement

Was gibt es Neues zur Gicht?

Berichte vom ACR 2018
  • J. Braun
  • U. KiltzEmail author
Forschung aktuell
  • 15 Downloads

Der Artikel gibt eine Übersicht über 25 Studien zur Gicht, die während des American Congress of Rheuamtology (ACR) 2018 vorgestellt wurden. Es werden Daten zur Epidemiologie, Krankheitslast und Komorbidität sowie zu Aspekten der Diagnose und Therapie vorgestellt. Allen vorgestellten Studien ist gemeinsam, dass das Management der Gicht verbesserungswürdig ist und insbesondere die Einhaltung des Serumharnsäurezielwertes sowie die Prophylaxe von Gichtattacken ein Schlüsselelement in der Behandlung von Gichtpatienten darstellen sollten.

Epidemiologische Daten zur Gicht

Die Gicht ist wahrscheinlich die häufigste Form von entzündlicher Arthritis in Europa, aktuelle populationsbasierte Daten fehlen jedoch. Die hier diskutierte Studie aus Deutschland zielte darauf ab, eine aktuelle Analyse der Prävalenz und Inzidenz von Gicht, den damit verbundenen Komorbiditäten und aktueller Behandlungsmuster zu ermitteln. Hierfür wurden Daten der InGef-Forschungsdatenbank verwendet, die Stichproben aus etwa...

What is new on gout?

Report from ACR 2018

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

J. Braun und U. Kiltz geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Kiltz U, Perez-Ruiz F, Uhlig T et al (2018) The prevalence and incidence of gout, its associated comorbidities and treatment pattern: An epidemiological study from Germany. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 1131)Google Scholar
  2. 2.
    Zhu Y, Pandya BJ, Choi HK (2010) Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 63(10):3136–3141CrossRefGoogle Scholar
  3. 3.
    Chen-Xu M, Yokose C, Pillinger M, Choi HK (2018) Contemporary prevalence of gout and hyperuricemia in the United States (National Health and Nutrition Examination Survey [NHANES] 2015–2016) and decadal trends (NHANES 2007–2016). 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 1149)Google Scholar
  4. 4.
    Chen-Xu M, Yokose C, Pillinger M, Choi HK (2018) Prevalence of urate-lowering therapy use and target urate level achievement among gout patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007–2014). 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 2237)Google Scholar
  5. 5.
    Chen-Xu M, Yokose C, Pillinger M, Choi HK (2018) Contemporary comorbidity burden of gout and hyperuricemia in the US during the past decade (National Health And Nutrition Examination Survey [NHANES] 2007–2016). 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 2236)Google Scholar
  6. 6.
    Khanna PP, Taylor DCA, Fu AC, Morlock R (2018) Patient-reported burden of gout in 2017 from the United States. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 870)Google Scholar
  7. 7.
    Khanna PP, Taylor DCA, Fu AC et al (2018) What did patients from the US think about their gout in 2017? 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 1273)Google Scholar
  8. 8.
    Singh JA, Cleveland J (2018) Gout and chronic pain in older adults: A medicare claims study. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 1126)Google Scholar
  9. 9.
    Murugesan V, Tran J (2018) Epidemiological characteristics of inpatient admissions for acute inflammatory gout arthropathy and factors affecting length of stay: A national level study. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 1124)Google Scholar
  10. 10.
    Singh G, Mithal A (2018) Not just a swollen big toe: Increasing all-cause hospitalizations in patients with gout in the United States: 1993–2014. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 2249)Google Scholar
  11. 11.
    Taylor DCA, Jaffe D, Hoshen M et al (2018) Is the serum uric acid therapeutic target protective of chronic kidney disease, cardiovascular disease, and mortality for patients with gout? A longitudinal study. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 872)Google Scholar
  12. 12.
    Proudman C, Lester S, Gonzalez-Chica D et al (2018) Gout, flares and allopurinol use: A population based study. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 2220)Google Scholar
  13. 13.
    Kuo CF, Grainge MJ, Mallen C et al (2015) Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann Rheum Dis 74(4):661–667CrossRefGoogle Scholar
  14. 14.
    Panginikkod S, Raja A, Rajabirostami E et al (2018) A survey on gout-related knowledge among internal medicine residents. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 194)Google Scholar
  15. 15.
    Kiltz U, Smolen J, Bardin T et al (2017) Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 76(4):632–638CrossRefGoogle Scholar
  16. 16.
    White WB, Saag KG, Becker MA et al (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200–1210CrossRefGoogle Scholar
  17. 17.
    Saag K, Becker MA, White WB et al (2018) General safety of febuxostat and allopurinol in a cardiovascular outcomes study in patients with gout. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 873)Google Scholar
  18. 18.
    Quilis N, Ranieri L, Sanchez-Paya J, Andrés M (2018) New cardiovascular events in patients with gout treated with xanthine-oxidase inhibitors: An inception cohort analysis. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. L01)Google Scholar
  19. 19.
    Perez-Ruiz F, Richette P, Stack A et al (2018) Failure to reach serum urate target is associated with elevated mortality in gout. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 869)Google Scholar
  20. 20.
    Rai SK, Lu N, Yokose C et al (2018) Preventing a large majority of incident gout cases by modifying key risk factors: Findings from a prospective cohort of 44,629 men over 26 years. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 874)Google Scholar
  21. 21.
    DiFiore M, Wong M, Chang J (2018) Diet modification for gout patients: Effects on gout attacks and risk factors for metabolic syndrome. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 1132)Google Scholar
  22. 22.
    Gamala M, Jacobs JWG, Linn-Rasker S et al (2018) Dual-energy CT for the diagnosis of gout: A prospective study in patients with no prior history of gout. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 1275)Google Scholar
  23. 23.
    Yokose C, Zhang Y, Dalbeth N et al (2018) Patterns of monosodium urate deposition on dual-energy CT in gout patients on urate-lowering therapy. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 866)Google Scholar
  24. 24.
    Yokose C, Dalbeth N, Nicolaou S et al (2018) Monosodium urate deposition distribution in the knees, hands, and feet of treated gout patients: A dual-energy CT study. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 2235)Google Scholar
  25. 25.
    Lautour H, Taylor WJ, Adebajo A et al (2016) Development of preliminary de remission criteria for gout using Delphi and 1000Minds consensus exercises. Arthritis Care Res (Hoboken) 68(5):667–672CrossRefGoogle Scholar
  26. 26.
    Dalbeth N, Frampton C, Fung M et al (2018) Construct validity of provisional remission criteria for gout: A dual energy CT study. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 2222)Google Scholar
  27. 27.
    Yokose C, Zhang Y, Dalbeth N et al (2018) A prospective study examining the prevalence of CT erosions in the feet and ankles of patients with gout treated with allopurinol. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 1277)Google Scholar
  28. 28.
    Dalbeth N, Billington K, Doyle A et al (2018) Allopurinol dose escalation slows progression of CT bone erosion in people with gout: Imaging sub-study of a randomized control trial. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 2969)Google Scholar
  29. 29.
    Azeem R, Sands E, Johnston L et al (2018) Initial phase 2 clinical data of SEL-212 in symptomatic gout patients: Measurement of dissolution of urate deposits associated with monthly dosing of a pegylated uricase (pegadricase) with Svp-rapamycin by dual energy computed tomography. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 2205)Google Scholar
  30. 30.
    Saag K, Feinman M, Baraf HSB et al (2018) Initial pegloticase serum levels predict persistent responsiveness in patients with chronic refractory gout. 2018 ACR/ARHP Annual Meeting, Chicago, 19.–24.10.2018 (abstract nr. 1284)Google Scholar
  31. 31.
    Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE (2017) Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. Arthritis Res Ther 19(1):191CrossRefGoogle Scholar
  32. 32.
    Richette P, Doherty M, Pascual E et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29–42CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Rheumazentrum RuhrgebietHerneDeutschland
  2. 2.Ruhr Universität BochumBochumDeutschland

Personalised recommendations